DAWN

DAWN R&D to Revenue

93.65%Fiscal year

Period ending:

DAWN FY R&D/Revenue%
DAWN FY R&D/Revenue194.44%-20.83%
2019-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

DAWN r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 7 observations from Dec 31, 2019 to Dec 31, 2025.

Day One Biopharmaceuticals Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
93.6485%
173.605%
0%
0%
0%
0%
0%

Compare r&d to revenue

All DAWN financial metrics · DAWN stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.